Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L
Clinique des Maladies Cutanées, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris Cedex 10, France.
Ann Dermatol Venereol. 2000 Feb;127(2):171-4.
Teratogenicity and neuropathy are the well known serious side effects induced by thalidomide. We describe 5 cases of thrombotic events occurring within a brief delay after the onset of thalidomide in a manner that suggests that thalidomide could have acted as a precipiting or as a starting factor in these events.
Five patients including 4 patients with lupus erythematosus (1 discoid lupus, 1 subacute lupus and 2 systemic lupus erythematosus) and one patient with a severe atopic dermatitis, all without previous history of vascular events, developed an arterial thrombosis (2 cases) or a venous thrombosis (3 cases), severe in 4 cases, few days or weeks after the onset of thalidomide treatment (50 to 100 mg daily).
All the patients had risk factors of thrombosis: the presence of antiphospholipids and/or anticardiolipin antibodies in lupus erythematosus patients and a trauma in the atopic case. However the absence of a previous story of thrombosis, its rapid occurrence after the onset of thalidomide and its severity are intriguing. In addition, recent studies demonstrate that thalidomide has various effects that would act, among other things, on angiogenesis. Thus, we think that a doubt exists on a negative effect of thalidomide in thrombosis risk factors patients and that this hypothesis has to be confirmed.
致畸性和神经病变是沙利度胺引起的众所周知的严重副作用。我们描述了5例在开始使用沙利度胺后短期内发生血栓事件的病例,这些病例表明沙利度胺可能是这些事件的诱发因素或起始因素。
5例患者,包括4例红斑狼疮患者(1例盘状狼疮、1例亚急性狼疮和2例系统性红斑狼疮)和1例重度特应性皮炎患者,既往均无血管事件病史,在开始使用沙利度胺治疗(每日50至100毫克)后数天或数周内发生了动脉血栓形成(2例)或静脉血栓形成(3例),其中4例病情严重。
所有患者均有血栓形成的危险因素:红斑狼疮患者存在抗磷脂和/或抗心磷脂抗体,特应性皮炎患者有创伤史。然而,既往无血栓形成病史、在开始使用沙利度胺后迅速发生血栓形成及其严重性令人关注。此外,最近的研究表明,沙利度胺具有多种作用,其中包括对血管生成的作用。因此,我们认为对于沙利度胺对有血栓形成危险因素患者的负面影响存在疑问,这一假设有待证实。